Paris-based TISSIUM has secured a €60M financing package, a completed €30M Series D2, plus a €30M facility from the European Investment Bank, to fuel its US commercial rollout and advance a pipeline spanning nerve repair, hernia, and cardiovascular surgery.
Its first product, COAPTIUM® CONNECT, is the only FDA-authorised sutureless nerve repair system in the world; a 12-patient clinical study showed 100% of participants regained full function and reported no pain one year after surgery.
TISSIUM has now raised over $200M since 2013, entering the peripheral nerve repair devices market, valued at $13.4B today and projected to reach $30.5B by 2033.
For decades, surgeons repairing a severed nerve have done the same thing: stitch two fragile ends back together under a microscope, hoping the suture needle doesn’t damage the tissue it is trying to heal. A recent meta-analysis found that only 54% of patients achieve meaningful recovery with that method.
TISSIUM, a Paris-based medtech built on research from MIT and Harvard’s Brigham and Women’s Hospital, has spent over a decade building the alternative, and today it closed a €60 million financing package to bring it to scale.
